ME Therapeutics Holdings Inc.
METX
CNSX
| 11/30/2025 | 08/31/2025 | 05/31/2025 | 02/28/2025 | 11/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -17.34% | -25.21% | -55.73% | 83.97% | -15.56% |
| Depreciation & Amortization | 150.00% | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.82% | 23.31% | -34.93% | 32.50% | -16.26% |
| Operating Income | -21.82% | -23.31% | 34.93% | -32.50% | 16.26% |
| Income Before Tax | -15.88% | -8.25% | 30.93% | -30.81% | 12.81% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -15.88% | -8.25% | 30.93% | -30.81% | 12.81% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.88% | -8.25% | 30.93% | -30.81% | 12.81% |
| EBIT | -21.82% | -23.31% | 34.93% | -32.50% | 16.26% |
| EBITDA | -22.04% | -19.57% | 37.01% | -28.43% | 19.13% |
| EPS Basic | 2.30% | 7.78% | 41.38% | -15.56% | 18.69% |
| Normalized Basic EPS | 1.85% | 8.77% | 41.76% | -17.86% | 19.40% |
| EPS Diluted | 2.30% | 7.78% | 42.18% | 5.41% | 18.69% |
| Normalized Diluted EPS | 1.85% | 8.77% | 41.76% | -17.86% | 19.40% |
| Average Basic Shares Outstanding | 18.27% | 17.52% | 17.94% | 13.76% | 6.91% |
| Average Diluted Shares Outstanding | 18.27% | 17.52% | 17.94% | 13.76% | 6.91% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |